Canaccord lowered the firm’s price target on Biogen to $298 from $308 and keeps a Buy rating on the shares. The firm updated its model following Q2 results and is driven by higher gross margin, modestly higher SG&A and lower R&D expense estimates in 2024E.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen price target lowered to $190 from $200 at Barclays
- Biogen raises FY24 EPS view to $15.75-$16.25, consensus $15.58
- Biogen reports Q2 EPS $5.28, consensus $4.02
- New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The Alzheimer’s Association International Conference (AAIC) 2024
- Biogen presents new data on LEQEMBI in early Alzheimer’s Disease patients